Clinical Trial Update: Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick [Phase 2]

View source ↗

Summary

A Phase 2 trial update for the Maximal Use Systemic Exposure (MUSE) study of Levulan Kerastick (5-ALA) in actinic keratosis, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LEVULAN KERASTICK (AMINOLEVULINIC ACID HYDROCHLORIDE)

Snippet

Sponsor: DUSA Pharmaceuticals, Inc. | Conditions: Keratosis, Actinic | Phase 2 | Status: COMPLETED | Results posted: 2017-01-13